Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat

Jin-Ya Wang, Ya-Ni Huang, Chong-Chi Chiu, David Tweedie, Wei-Ming Luo, Chaim Gideon Pick, Szu-Yi Chou, Yu Luo, Barry J. Hoffer, Nigel H. Greig, Jia Yi Wang

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Traumatic brain injury (TBI) is a global health concern that typically causes emotional disturbances and cognitive dysfunction. Secondary pathologies following TBI may be associated with chronic neurodegenerative disorders and an enhanced likelihood of developing dementia-like disease in later life. There are currently no approved drugs for mitigating the acute or chronic effects of TBI. Methods: The effects of the drug pomalidomide (Pom), an FDA-approved immunomodulatory agent, were evaluated in a rat model of moderate to severe TBI induced by controlled cortical impact. Post-TBI intravenous administration of Pom (0.5 mg/kg at 5 or 7 h and 0.1 mg/kg at 5 h) was evaluated on functional and histological measures that included motor function, fine more coordination, somatosensory function, lesion volume, cortical neurodegeneration, neuronal apoptosis, and the induction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Results: Pom 0.5 mg/kg administration at 5 h, but not at 7 h post-TBI, significantly mitigated the TBI-induced injury volume and functional impairments, neurodegeneration, neuronal apoptosis, and cytokine mRNA and protein induction. To evaluate underlying mechanisms, the actions of Pom on neuronal survival, microglial activation, and the induction of TNF-α were assessed in mixed cortical cultures following a glutamate challenge. Pom dose-dependently ameliorated glutamate-mediated cytotoxic effects on cell viability and reduced microglial cell activation, significantly attenuating the induction of TNF-α. Conclusions: Post-injury treatment with a single Pom dose within 5 h significantly reduced functional impairments in a well-characterized animal model of TBI. Pom decreased the injury lesion volume, augmented neuronal survival, and provided anti-inflammatory properties. These findings strongly support the further evaluation and optimization of Pom for potential use in clinical TBI.

Original languageEnglish
Article number168
JournalJournal of Neuroinflammation
Volume13
Issue number1
DOIs
Publication statusPublished - Jun 28 2016

Fingerprint

Glutamic Acid
Wounds and Injuries
Apoptosis
Cytokines
Traumatic Brain Injury
pomalidomide
Affective Symptoms
Interleukin-1
Neurodegenerative Diseases
Pharmaceutical Preparations
Intravenous Administration
Dementia
Interleukin-6
Cell Survival
Anti-Inflammatory Agents
Animal Models
Pathology
Messenger RNA
Proteins
Therapeutics

Keywords

  • Controlled cortical impact
  • Glutamate excitotoxicity
  • Interleukin-1β
  • Interleukin-6
  • Neuroinflammation
  • Neuronal apoptosis
  • Pomalidomide
  • Thalidomide
  • Traumatic brain injury
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Neuroscience(all)
  • Cellular and Molecular Neuroscience
  • Neurology
  • Immunology

Cite this

Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. / Wang, Jin-Ya; Huang, Ya-Ni; Chiu, Chong-Chi; Tweedie, David; Luo, Wei-Ming; Pick, Chaim Gideon; Chou, Szu-Yi; Luo, Yu; Hoffer, Barry J.; Greig, Nigel H.; Wang, Jia Yi.

In: Journal of Neuroinflammation, Vol. 13, No. 1, 168, 28.06.2016.

Research output: Contribution to journalArticle

Wang, Jin-Ya ; Huang, Ya-Ni ; Chiu, Chong-Chi ; Tweedie, David ; Luo, Wei-Ming ; Pick, Chaim Gideon ; Chou, Szu-Yi ; Luo, Yu ; Hoffer, Barry J. ; Greig, Nigel H. ; Wang, Jia Yi. / Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. In: Journal of Neuroinflammation. 2016 ; Vol. 13, No. 1.
@article{6ab6407f0a464d07bc28fc8db2e37db6,
title = "Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat",
abstract = "Background: Traumatic brain injury (TBI) is a global health concern that typically causes emotional disturbances and cognitive dysfunction. Secondary pathologies following TBI may be associated with chronic neurodegenerative disorders and an enhanced likelihood of developing dementia-like disease in later life. There are currently no approved drugs for mitigating the acute or chronic effects of TBI. Methods: The effects of the drug pomalidomide (Pom), an FDA-approved immunomodulatory agent, were evaluated in a rat model of moderate to severe TBI induced by controlled cortical impact. Post-TBI intravenous administration of Pom (0.5 mg/kg at 5 or 7 h and 0.1 mg/kg at 5 h) was evaluated on functional and histological measures that included motor function, fine more coordination, somatosensory function, lesion volume, cortical neurodegeneration, neuronal apoptosis, and the induction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Results: Pom 0.5 mg/kg administration at 5 h, but not at 7 h post-TBI, significantly mitigated the TBI-induced injury volume and functional impairments, neurodegeneration, neuronal apoptosis, and cytokine mRNA and protein induction. To evaluate underlying mechanisms, the actions of Pom on neuronal survival, microglial activation, and the induction of TNF-α were assessed in mixed cortical cultures following a glutamate challenge. Pom dose-dependently ameliorated glutamate-mediated cytotoxic effects on cell viability and reduced microglial cell activation, significantly attenuating the induction of TNF-α. Conclusions: Post-injury treatment with a single Pom dose within 5 h significantly reduced functional impairments in a well-characterized animal model of TBI. Pom decreased the injury lesion volume, augmented neuronal survival, and provided anti-inflammatory properties. These findings strongly support the further evaluation and optimization of Pom for potential use in clinical TBI.",
keywords = "Controlled cortical impact, Glutamate excitotoxicity, Interleukin-1β, Interleukin-6, Neuroinflammation, Neuronal apoptosis, Pomalidomide, Thalidomide, Traumatic brain injury, Tumor necrosis factor-α",
author = "Jin-Ya Wang and Ya-Ni Huang and Chong-Chi Chiu and David Tweedie and Wei-Ming Luo and Pick, {Chaim Gideon} and Szu-Yi Chou and Yu Luo and Hoffer, {Barry J.} and Greig, {Nigel H.} and Wang, {Jia Yi}",
year = "2016",
month = "6",
day = "28",
doi = "10.1186/s12974-016-0631-6",
language = "English",
volume = "13",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat

AU - Wang, Jin-Ya

AU - Huang, Ya-Ni

AU - Chiu, Chong-Chi

AU - Tweedie, David

AU - Luo, Wei-Ming

AU - Pick, Chaim Gideon

AU - Chou, Szu-Yi

AU - Luo, Yu

AU - Hoffer, Barry J.

AU - Greig, Nigel H.

AU - Wang, Jia Yi

PY - 2016/6/28

Y1 - 2016/6/28

N2 - Background: Traumatic brain injury (TBI) is a global health concern that typically causes emotional disturbances and cognitive dysfunction. Secondary pathologies following TBI may be associated with chronic neurodegenerative disorders and an enhanced likelihood of developing dementia-like disease in later life. There are currently no approved drugs for mitigating the acute or chronic effects of TBI. Methods: The effects of the drug pomalidomide (Pom), an FDA-approved immunomodulatory agent, were evaluated in a rat model of moderate to severe TBI induced by controlled cortical impact. Post-TBI intravenous administration of Pom (0.5 mg/kg at 5 or 7 h and 0.1 mg/kg at 5 h) was evaluated on functional and histological measures that included motor function, fine more coordination, somatosensory function, lesion volume, cortical neurodegeneration, neuronal apoptosis, and the induction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Results: Pom 0.5 mg/kg administration at 5 h, but not at 7 h post-TBI, significantly mitigated the TBI-induced injury volume and functional impairments, neurodegeneration, neuronal apoptosis, and cytokine mRNA and protein induction. To evaluate underlying mechanisms, the actions of Pom on neuronal survival, microglial activation, and the induction of TNF-α were assessed in mixed cortical cultures following a glutamate challenge. Pom dose-dependently ameliorated glutamate-mediated cytotoxic effects on cell viability and reduced microglial cell activation, significantly attenuating the induction of TNF-α. Conclusions: Post-injury treatment with a single Pom dose within 5 h significantly reduced functional impairments in a well-characterized animal model of TBI. Pom decreased the injury lesion volume, augmented neuronal survival, and provided anti-inflammatory properties. These findings strongly support the further evaluation and optimization of Pom for potential use in clinical TBI.

AB - Background: Traumatic brain injury (TBI) is a global health concern that typically causes emotional disturbances and cognitive dysfunction. Secondary pathologies following TBI may be associated with chronic neurodegenerative disorders and an enhanced likelihood of developing dementia-like disease in later life. There are currently no approved drugs for mitigating the acute or chronic effects of TBI. Methods: The effects of the drug pomalidomide (Pom), an FDA-approved immunomodulatory agent, were evaluated in a rat model of moderate to severe TBI induced by controlled cortical impact. Post-TBI intravenous administration of Pom (0.5 mg/kg at 5 or 7 h and 0.1 mg/kg at 5 h) was evaluated on functional and histological measures that included motor function, fine more coordination, somatosensory function, lesion volume, cortical neurodegeneration, neuronal apoptosis, and the induction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Results: Pom 0.5 mg/kg administration at 5 h, but not at 7 h post-TBI, significantly mitigated the TBI-induced injury volume and functional impairments, neurodegeneration, neuronal apoptosis, and cytokine mRNA and protein induction. To evaluate underlying mechanisms, the actions of Pom on neuronal survival, microglial activation, and the induction of TNF-α were assessed in mixed cortical cultures following a glutamate challenge. Pom dose-dependently ameliorated glutamate-mediated cytotoxic effects on cell viability and reduced microglial cell activation, significantly attenuating the induction of TNF-α. Conclusions: Post-injury treatment with a single Pom dose within 5 h significantly reduced functional impairments in a well-characterized animal model of TBI. Pom decreased the injury lesion volume, augmented neuronal survival, and provided anti-inflammatory properties. These findings strongly support the further evaluation and optimization of Pom for potential use in clinical TBI.

KW - Controlled cortical impact

KW - Glutamate excitotoxicity

KW - Interleukin-1β

KW - Interleukin-6

KW - Neuroinflammation

KW - Neuronal apoptosis

KW - Pomalidomide

KW - Thalidomide

KW - Traumatic brain injury

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=84975830694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975830694&partnerID=8YFLogxK

U2 - 10.1186/s12974-016-0631-6

DO - 10.1186/s12974-016-0631-6

M3 - Article

VL - 13

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

IS - 1

M1 - 168

ER -